Applying The Multiproduct Manufacturing Model To Autologous Cell Therapy
By Vladimir Kostyukovsky, Biologics Consulting

Over decades, biopharmaceutical manufacturers and regulators have developed a thorough understanding of cross-contamination risks in facilities that manufacture multiple products and established effective controls to address them. These controls include physical separation of manufacturing areas, dedicated equipment when needed, controlled personnel and material movement, closed processing systems, validated cleaning procedures, and environmental monitoring.
The industry has also moved toward a science- and risk-based approach, recognizing that different products do not necessarily require completely dedicated manufacturing facilities. Appropriate combinations of engineering and procedural controls can provide an acceptable level of protection while allowing more efficient use of manufacturing capacity.
When applying this accumulated experience to autologous cell therapy manufacturing, however, a fundamental shift in perception is necessary. In autologous cell therapy, every patient manufacturing run represents an individual, patient-specific product. Consequently, a facility manufacturing a single CAR-T product for multiple patients is effectively manufacturing multiple distinct products, even when the manufacturing processes, equipment, and raw materials are identical.
This distinction has important implications for facility design, manufacturing operations, contamination control strategies, and quality risk management.
Autologous Cell Therapy Manufacturing Batches Are Designated For An Individual Patient
The development of autologous cell therapies, particularly CAR-T products, has introduced a manufacturing model that differs substantially from conventional biopharmaceutical production.
In traditional biologics manufacturing, a single production batch may generate hundreds or thousands of doses from a common manufacturing process. Product identity is maintained through controlled manufacturing records, equipment status, material traceability, and batch segregation.
Autologous cell therapy manufacturing operates differently. Each patient provides the starting biological material, which is processed individually and returned to that same patient. The starting material is unique, the manufacturing run is patient-specific, and the final product must retain its identity and integrity throughout the entire manufacturing process.
This creates two distinct but related risks: cross-contamination between patient manufacturing runs and product mix-ups resulting in administration of a product to the wrong patient.
The industry has historically addressed cross-contamination by separating different products through facility design, equipment dedication, cleaning validation, and procedural controls. However, applying these approaches to autologous manufacturing presents new challenges. Manufacturing capacity must accommodate multiple patient runs, often conducted simultaneously, while maintaining strict separation and traceability.
The FDA's 2008 guidance on somatic cell therapy manufacturing already emphasized product tracking and segregation, including the need to prevent mixing of products in incubators, hoods, and cryopreservation units. These principles remain highly relevant as autologous manufacturing operations become increasingly complex.
Thankfully, we have a roadmap to adapt established biopharmaceutical principles to a manufacturing environment in which every patient run must be treated as an individual product.
Step 1: Recognize That Every Patient Run Is A Separate Product
The most important starting point is to establish a clear definition of a manufacturing product or batch in an autologous facility.
A facility manufacturing one CAR-T therapy for 20 patients does not manufacture one product in 20 batches from a cross-contamination perspective. It is manufacturing 20 patient-specific products using a common manufacturing process.
This distinction should drive the facility contamination control strategy.
The consequences of cross-contamination may include unintended transfer of cells, genetic material, biological agents, or other patient-derived material. In addition to product quality concerns, the potential clinical consequences must be considered.
Step 2: Apply Established Segregation Principles
The conventional biopharmaceutical industry has long recognized physical segregation as one of the most effective ways to prevent cross-contamination.
Depending on the process and risk assessment, segregation can be achieved through:
- Separate manufacturing rooms or suites
- Dedicated isolators or biological safety cabinets
- Physically separated processing equipment
- Dedicated or appropriately segregated incubators and cryopreservation storage
- Defined personnel and material movement pathways
- Segregated storage of patient-specific materials and intermediates
Not every operation necessarily requires a separate cleanroom. However, the manufacturer should be able to demonstrate that the selected level of segregation is appropriate for the contamination risks associated with the process.
Attention should be given to operations involving open manipulation of patient-derived material. For example, two patient manufacturing runs conducted simultaneously in separate closed processing systems may present a different risk profile from two open manipulations performed in the same biological safety cabinet.
The assessment should consider not only the processing equipment but also the surrounding environment, operator activities, material transfers, and potential for accidental contact.
Step 3: Use Closed Systems And Single-Use Technologies As Primary Engineering Controls
The development of closed automated manufacturing platforms and single-use technologies has significantly improved the industry's ability to control contamination. However, a closed process should not automatically be considered to be a completely isolated process.
The manufacturer must evaluate potential contamination pathways, including:
- External surfaces of disposable tubing assemblies and bags
- Equipment interfaces and connection points
- If applicable, reusable equipment components
- Sampling operations and process interventions
- Transfer of materials between manufacturing areas
For example, using separate disposable product-contact assemblies for Patient A and Patient B substantially reduces the risk associated with shared product-contact surfaces. Nevertheless, the equipment itself may still be shared. The manufacturer's risk assessment should therefore address how the external surfaces, equipment interfaces, and surrounding work areas are controlled between patient runs.
Step 4: Establish A Patient-Specific Cleaning And Changeover Strategy
Traditional cleaning validation may not be applicable for single-use systems. However, autologous cell therapy manufacturers should recognize that the potential transfer of viable cells, residual cellular material, genetic material, and infectious agents may require additional controls and verification methods.
The cleaning and changeover strategy should be developed based on the equipment design and manufacturing process.
It should address:
- Removal of patient-derived biological material
- Cleaning and disinfection of reusable equipment and surfaces
- Decontamination of equipment interfaces and external surfaces
- Appropriate contact times and effectiveness of disinfectants
- Verification of cleaning effectiveness
- Defined equipment release criteria before the next patient manufacturing run
Step 5: Treat Patient Identity As An Essential Component Of Contamination Control
One of the most important lessons from conventional biopharmaceutical manufacturing is that preventing cross-contamination and preventing product mix-ups are closely related but distinct objectives.
In autologous cell therapy, both must be addressed.
An end-to-end chain-of-identity and chain-of-custody system should be maintained from collection of the starting material through manufacturing, storage, shipment, and administration.
Practical controls include:
- Unique patient identifiers assigned before material receipt
- Patient-specific labeling of all containers and process intermediates
- Barcode-based material identification and verification
- Electronic or independently verified checks at critical manufacturing steps
- Segregated storage locations
- Reconciliation of patient-specific materials at process completion
- Documented verification before product release and shipment
For example, a manufacturing operation may successfully prevent biological cross-contamination between two patient runs but still experience a product mix-up during transfer to cryopreservation storage. The outcome could be equally serious. Consequently, identity controls must be integrated into the overall contamination control strategy rather than managed as an entirely separate administrative activity.
Step 6: Develop A Comprehensive Patient-To-Patient Contamination Risk Assessment
Finally, manufacturers should adapt conventional multiproduct facility risk assessment methodologies to the patient-specific manufacturing environment. The assessment should evaluate each manufacturing step and identify potential pathways for transfer of biological material between patient runs.
It should consider the following:
- Simultaneous versus sequential processing
- Open versus closed operations
- Shared versus dedicated equipment
- Product-contact and non-product-contact surfaces
- Personnel and material movement
- Environmental and heating, ventilation, and air conditioning (HVAC) considerations
- Equipment cleaning and changeover
- Storage and cryopreservation
- Deviations, spills, and unexpected process interruptions
The resulting assessment should establish appropriate engineering and procedural controls and identify where additional segregation or dedicated equipment is justified.
Importantly, the assessment should not simply conclude that the manufacturing platform is closed or that disposable materials are used. It should demonstrate how these measures, together with other controls, prevent transfer between patient manufacturing runs.
Obstacles To Adapting Traditional Biological Methods
Although conventional biopharmaceutical manufacturing experience provides a strong foundation, several factors complicate its application to autologous cell therapy.
First, autologous manufacturing often operates under significant capacity and scheduling constraints. Dedicated rooms, equipment, and personnel for every patient run may be economically and operationally impractical. Manufacturers must therefore establish an appropriate balance between physical segregation, closed processing, and procedural controls.
Second, the extensive use of single-use technologies can create a false sense of security. Disposable product-contact assemblies reduce certain contamination risks but do not eliminate potential transfer through equipment exteriors, shared workspaces, operators, or environmental pathways.
Third, autologous starting materials may present different biological risks depending on the patient population and donor characteristics. For example, materials from patients carrying certain infectious agents may require additional segregation and handling precautions.
Finally, there is no universal facility design or segregation model that can be applied to every autologous cell therapy process. The appropriate strategy depends on the biological characteristics of the product, manufacturing platform, degree of process closure, facility configuration, and operational model.
These limitations reinforce the importance of product- and process-specific risk assessments rather than relying on generalized assumptions about the effectiveness of a particular technology or facility design.
Treat Every Patient Run As Its Own ProductAutologous cell therapy manufacturers should take full advantage of the accumulated experience in preventing cross-contamination between different products rather than treating patient-specific manufacturing as an entirely new cross-contamination control challenge.
The critical difference is recognizing that every patient manufacturing run represents an individual product. This requires extending conventional multiproduct manufacturing principles to patient-to-patient mix-up prevention.
A manufacturing facility producing a single CAR-T therapy for multiple patients should be designed, operated, and controlled with the same fundamental discipline applied to a facility manufacturing multiple distinct biopharmaceutical products.
Patient-level protection can be achieved even in shared manufacturing environments with a scientifically justified combination of engineering controls, physical segregation, closed processing, cleaning and decontamination procedures, and patient-specific traceability that adequately protects every manufacturing run.
Ultimately, the success of autologous cell therapy manufacturing depends not only on producing a safe and effective therapy but also on ensuring that the product administered to each patient is exclusively that patient's product.
References:
- FDA (2008). Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Controls Information for Human Somatic Cell Therapy Investigational New Drug Applications. Particularly relevant to product tracking, segregation, and patient-specific identity. FDA guidance.
- FDA (2024). Considerations for the Use of Human- and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products. FDA guidance.
- EMA (2008). Guideline on Human Cell-Based Medicinal Products. EMA document.
- Concise Review (2013). Guidance in Developing Commercializable Autologous/Patient-Specific Cell Therapy Manufacturing. Stem Cells Translational Medicine.
- Health Canada. Policy Position Paper — Autologous Cell Therapy Products. Addresses risks including between-patient cross-contamination. Health Canada.
About The Author:
Vladimir Kostyukovsky is a senior consultant, CMC, with Biologics Consulting Group. Previously, he was founder of RibbitBio LLC, an independent biopharmaceutical consulting firm. He works with biotech founders, virtual biopharmaceutical executives, and CMC and regulatory leaders to address complex manufacturing and product supply challenges. His experience spans biologics, autologous and allogeneic cell therapy, and in vivo gene therapy modalities. Through RibbitBio, Vladimir provides strategic guidance and hands-on technical support to help establish reliable clinical and commercial manufacturing operations.